Skip to main content
Sign In

University of Colorado Denver Hematology, Blood Cancer, Bone Marrow Transplant Program

 Blood Cancer, Bone Marrow Transplant Program Logo
 

Clinical Trials

​See what human subject trials are accepting applicants


For more information click the study identifier or search the identifier number at clinicaltrials.gov.

 Acute Lymphoblastic Leukemia (non transplant)

ClinicalTrials.gov
Identifier
Study Title ​Study Coordinator
NCT01132573 A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995, IND#61198) plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults with Relapsed and Refractory Disease​ ​Nicole Adler, 720-848-0678
​​1

 Acute Myeloid Leukemia (non-transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
​NCT02203773 ​A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy. ​Sejal Tailor, 720-848-3773​

NCT02074839​​

​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation. ​Sejal Tailor,  720-848-3773
NCT01743859 Celgene RV-AML-PI - 0759: Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia Aaron Fullerton, 720-848-0290​
NCT01546038 A Phase 1B/2 Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-c, or Decitabine in Patients with Acute Myeloid Leukemia or High Risk Myelodyplastic Syndrome

Aaron Fullerton, 720-848-0290

NCT00840177 ​S0919, A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML) Emily Denoncourt, 720-848-0566
NCT01915498 ​A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation. ​Derek Schatz, 720-848-0628

​​​​​​​​10

 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT01886859 A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ​Nicole Adler, 720-848-0678
​​2

 Hodgkin Lymphoma (non transplant)

No current trials recruiting3

 Myelodysplastic Syndrome (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT02074839 ​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation.

​Sejal Tailor, 720-848-3773​

NCT01546038 A Phase 1B/2 Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-c, or Decitabine in Patients with Acute Myeloid Leukemia or High Risk Myelodyplastic Syndrome ​Aaron Fullerton, 720-848-0290
​​NCT01915498 ​A Phase I, Multicenter, Open-Label, Dose-Escalationa, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation ​Sejal Tailor, 720-848-3773​
​​​​​4

 Myeloma (non transplant)

ClinicalTrials.gov Identifier Study Title Study Coordinator
NCT01734928 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in subjects with Relapsed and Refractory Multiple Myeloma 

Aaron Fullerton, 720-848-0290

5

 Non Hodgkin Lymphoma: Follicular & other indolent (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
​​6

 Non Hodgkin Lymphoma: Mantle Cell (non transplant)

​No current trials recruiting7

 Non Hodgkin Lymphoma: DLBCL and other aggressive (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
​​​8

 Transplant

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator​
​NCT01841333 ​A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse ​​Emily Denoncourt,
720-848-0566
NCT01610414 ​GSK 115523: A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B candidate vaccine when administered intramuscularly on a two-dose schedule to adult autologous haematopoietic stem cell transplant (HCT) recipients. Greg Hemenway, 720-848-8026
NCT01769170 ​Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematolpoietic Stem Cell Transplant Recipients Emily Denoncourt, 720-848-0566​
​​9